Related Experiment Videos
Cancer immunoprevention
Pier-Luigi Lollini1, Carla De Giovanni, Tania Pannellini
1Cancer Research Section, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I-40126 Bologna, Italy. pierluigi.lollini@unibo.it
Future Oncology (London, England)
|March 25, 2006
Summary
Cancer immunoprevention, stimulating the immune system before tumor onset, effectively blocked mammary carcinogenesis in preclinical models. This approach, utilizing antibodies and cytokines, shows promise for clinical trials.
Area of Science:
- Oncology
- Immunology
- Cancer Prevention
Background:
- Cancer immunoprevention is an emerging strategy focusing on immune system activation prior to tumor development.
- Preclinical studies demonstrate its efficacy in various carcinogen-induced and autochthonous tumor models.
Purpose of the Study:
- To evaluate the effectiveness of immunoprevention in blocking mammary carcinogenesis.
- To explore the potential of combining immunoprevention with chemoprevention strategies.
Main Methods:
- Utilized vaccines composed of cells or DNA plasmids with adjuvants in HER-2/neu transgenic mice.
- Investigated the roles of antibodies and T-cell-derived cytokines as key mediators.
Main Results:
- Complete blockade of mammary carcinogenesis was achieved in vaccinated mice.
- Immunoprevention mediators differ from immunotherapy, focusing on antibodies and cytokines rather than cytotoxic T-cells.
Conclusions:
- Preclinical success indicates that cancer immunoprevention warrants progression to clinical testing.
- Combination therapy with chemopreventive agents like tamoxifen or COX-2 inhibitors may offer advantages.